Literature DB >> 21362546

PI3K p110β: more tightly controlled or constitutively active?

Peter K Vogt1.   

Abstract

Year:  2011        PMID： 21362546     DOI： 10.1016/j.molcel.2011.02.017

Source DB:  PubMed          Journal:  Mol Cell        ISSN： 1097-2765            Impact factor:   17.970


× No keyword cloud information.
  11 in total

Review 1.  Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling.

Authors:  Leszek Kotula
Journal:  FEBS Lett       Date:  2012-05-19       Impact factor: 4.124

Review 2.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

3.  The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

Authors:  Tamara Utermark; Trisha Rao; Hailing Cheng; Qi Wang; Sang Hyun Lee; Zhigang C Wang; J Dirk Iglehart; Thomas M Roberts; William J Muller; Jean J Zhao
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

4.  PI3King the right partner: unique interactions and signaling by p110β.

Authors:  Hashem A Dbouk
Journal:  Postdoc J       Date:  2015-06

5.  Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.

Authors:  Ping Chen; Ya-Li Deng; Simon Bergqvist; Matthew D Falk; Wei Liu; Sergei Timofeevski; Alexei Brooun
Journal:  Protein Sci       Date:  2014-08-07       Impact factor: 6.725

Review 6.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 7.  PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.

Authors:  Benyi Li; Aijing Sun; Wencong Jiang; J Brantley Thrasher; Paul Terranova
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

8.  Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells.

Authors:  Hasan Mahmud; Guru P Maiti; Murali K Mamidi; Mariana T Mendez; Stacey M Fernandes; Sara K Vesely; Jennifer Holter-Chakrabarty; Jennifer R Brown; Asish K Ghosh
Journal:  Leukemia       Date:  2022-05-14       Impact factor: 12.883

9.  PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

Authors:  Fabienne Schmit; Tamara Utermark; Sen Zhang; Qi Wang; Thanh Von; Thomas M Roberts; Jean J Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-15       Impact factor: 11.205

10.  Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).

Authors:  John E Burke; Roger L Williams
Journal:  Adv Biol Regul       Date:  2012-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.